Objective: To define values of normalized brain volume (NBV) that can be categorized as low, medium, or high, according to baseline characteristics of relapsing-remitting multiple sclerosis (RRMS) patients. Methods: Expected NBV (eNBV) was calculated for each patient based on age, disease duration, sex, baseline Expanded Disability Status Scale (EDSS), and T2-lesion volume, entering these variables into a multiple regression model run on 2342 RRMS patients (pooled FREEDOMS/FREEDOMS-II population). According to the difference between their observed NBV and their eNBV, patients were classified as having low NBV, medium NBV, or high NBV. We evaluated whether these NBV categories were clinically meaningful by assessing correlation with disability worsening. Results: The distribution of differences between observed NBV and eNBV was used to categorize patients as having low NBV, medium NBV or high NBV. Taking the high-NBV group as reference, the hazard ratios (HRs) for 2-year disability worsening, adjusted for treatment effect, were 1.23 (95% confidence interval (CI): 0.92-1.63, p = 0.16) for the medium NBV and 1.75 (95% CI: 1.26-2.44, p = 0.001) for the low NBV. The predictive value of NBV groups was preserved over 4 years. Treatment effect appeared more evident in low-NBV patients (HR = 0.58) than in medium-NBV (HR = 0.72) and in high-NBV (HR = 0.80) patients; however, the difference was not significant (p = 0.57). Conclusion: RRMS patients can be categorized into disability risk groups based on individual eNBV values according to baseline demographics and clinical characteristics.
Introduction
Magnetic resonance imaging (MRI)-derived measures of brain volume (BV) can be used to assess overall tissue damage in relapsing-remitting multiple sclerosis (RRMS). [1] [2] [3] [4] In RRMS patients, brain volume loss (BVL) has been proven to occur throughout the disease course, including the early stages, and progresses at a rate considerably higher than that of healthy adults. [5] [6] [7] [8] [9] [10] Recent work has defined relevant threshold values to discriminate pathological versus physiological BVL rates in patients with RRMS 11 and has demonstrated the relevance of BVL as a measure of central nervous system (CNS) tissue damage, 12 with a proposal to include BVL in composite measures assessing RRMS disease activity. 13 Many studies have shown that baseline BV and the rate of BVL correlate with disability worsening and are also predictive of future disability. [14] [15] [16] [17] Moreover, brain atrophy has been shown to be correlated to cognitive impairment, 18, 19 employment status, 20 and quality of life 21 in multiple sclerosis (MS) patients. Whereas the correlation between low BVs and disability worsening in patients with RRMS has been demonstrated at a group level, it is more difficult to establish at the individual level whether the volume of the brain measured in a single patient can be considered low or high. In this post hoc analysis, we evaluated the possibility of defining individualized values for normalized brain volume (NBV) for head size to classify an individual patient as having a low or a high volume of the brain according to the demographic characteristics and the disease status of the individual subject. The adjustment for baseline characteristics and for baseline Expanded Disability Status Scale (EDSS) which is the strongest indicator of damage is important since a low NBV value can be expected when the damage (EDSS) is high, but this is particularly worrisome if the EDSS is low. We then evaluated this classification by testing its ability to predict-onstudy disability worsening.
Materials and methods

Standard protocol approvals, registrations, and patient consents
The FREEDOMS and FREEDOMS II trials (ClinicalTrials.gov identifiers: NCT00289978 and NCT00355134, respectively) and their extensions were conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the ethical principles of the Declaration of Helsinki. 22, 23 The ethics committees and institutional review boards of all participating centers approved the study protocols. All participants provided written informed consent. 24, 25 Patients and study design The study design and inclusion/exclusion criteria of the FREEDOMS and FREEDOMS II trials have been previously described. 24, 25 Briefly, the studies included RRMS patients (diagnosed according to the revised McDonald criteria), aged 18-55 years who had a score of 0-5.5 on the EDSS and one or more documented relapses in the previous year or two or more relapses in the previous 2 years. The eligible patients were randomized (1:1:1) to receive fingolimod 0.5 or 1.25 mg/day, or placebo for 2 years. 24, 25 All patients who completed the 24-month FREEDOMS/ FREEDOMS II trial were eligible for the extension. Following Food and Drug Administration (FDA) approval of fingolimod 0.5 mg dose, all patients receiving fingolimod 1.25 mg in study extensions were switched to fingolimod 0.5 mg. The extension phase continued until the umbrella safety extension study (ClinicalTrials.gov identifier, NCT01201356) opened for enrollment for patients who participated in all completed fingolimod studies. 26, 27 Assessments Standardized neurological assessments, including determination of EDSS, were conducted at baseline and every 3 months. MRI scans were obtained at baseline, months 6, 12, and 24 or at the end of the study, if the patient discontinued the study prematurely. 24, 25 MRI lesion activity and BVL were assessed by a central reading site (Medical Image Analysis Center, Basel, Switzerland) that remained blinded for clinical data and randomization. MRI protocols and analysis methods have been detailed elsewhere. 24, 25 
Outcome measures
The NBV was assessed at baseline using Structural Image Evaluation using Normalization of Atrophy, Cross-sectional (SIENAX). 28 Disability worsening was defined as an increase in the EDSS score of ⩾1 point sustained for ⩾3 months (1.5 points if baseline EDSS = 0).
Statistical analysis
The analysis was run in two separate steps. In step 1, a cross-sectional analysis of baseline data was performed. Baseline factors that are correlated with baseline NBV were assessed for the pooled dataset from FREEDOMS and FREEDOMS II trials. A multivariate linear regression analysis, including age, sex, disease duration, EDSS, T2-lesion volume (T2LV), and trial indicator (representing the studies), was performed and the partial correlation coefficient of each factor (adjusted for all the other variables) with NBV was estimated. Variables with a skewed distribution (T2LV and disease duration) were transformed in three ordered groups defined by the tertiles of their distribution. Age and EDSS score were treated as continuous variables, whereas sex and trial were categorical variables. The "trial" effect was estimated and compared to the residual variability of NBV (after adjusting the regression model for all the other baseline characteristics) to understand the comparability of the NBV measure between the two trials, adjusting for the different population characteristics. The trial effect on NBV was evaluated using the greatest standardized mean difference (Cohen' 
where a is a constant and b, c, d, e, and f are the partial coefficients estimated by the regression model.
The difference between the observed NBV and the eNBV value from the statistical model for each patient indicates whether the patient has a NBV higher or lower than expected (according to demographic and disease status).
Based on the distribution of these differences, patients were categorized into three groups: low NBV for patients for whom the NBV was more than 1 standard deviation (SD) below the eNBV, medium NBV for patients for whom the NBV was within 1 SD from the eNBV, and high NBV for patients for whom the NBV was more than 1 SD above the eNBV.
In step 2, the prognostic values of the three defined NBV groups on disability (EDSS) change over 2 years were evaluated in the placebo-treated patients and in the overall population, adjusting for treatment effect. In both the FREEDOMS and FREEDOMS II trials, baseline characteristics were similar between the fingolimod 0.5 mg and 1.25 mg groups and, the two doses of fingolimod showed similar results across all efficacy outcomes (relapse rates, clinical disability worsening, and focal MRI lesion activity and BVL). Hence, this analysis was simplified by pooling the fingolimod 0.5 mg and 1.25 mg groups (presented together as the fingolimod group). The prognostic value of the NBV was also evaluated on the whole cohort (patients originally randomized to placebo and fingolimod arms) over the 4-year extension period. Finally, a differential fingolimod effect as compared to placebo according to the different baseline NBV groups was assessed.
The impact of the baseline NBV category, on the cumulative risk of 3-month confirmed disability progression (CDP) was analyzed using a Cox model. The fingolimod treatment effect on CDP for each baseline NBV category was evaluated by a treatment by group interaction test. The difference in the probability of worsening according to baseline NBV in placebo-and fingolimod-treated patients was displayed using Kaplan-Meier plots.
Results
NBV at baseline estimated from the patient's demographics and disease characteristics
Complete MRI and clinical baseline data were available for 2342 patients from the pooled intent-to-treat populations from FREEDOMS (N = 1267) and FREEDOMS II (N = 1075) studies. Table 1 reports the baseline characteristics of the patients included in this analysis. The overall baseline average NBV (±SD) was 1518 (±84) cm 3 and was similar between the FREEDOMS (1514 (±85) cm 3 ) and FREEDOMS II (1521 (±83) cm 3 ) populations, and the distributions were nearly superimposable. T2LV, EDSS, age, disease duration, and sex showed significant correlations with NBV (p < 0.001 for all; Table 2 ). The numerical details for the eNBV calculation are reported ( Table 2) , with examples of the calculation of eNBV for patients with different baseline and disease characteristics (Figure 1 ). The R 2 value of the model was 36% indicating that the variables included were able to account for 36% of the variance in baseline NBV among patients.
The distribution of the differences between the observed NBV and eNBV (calculated for each patient) is shown in Figure 2 (a). The SD of this distribution was 67 cm 3 and represented the between-patient variability in NBV not accounted for by the examined characteristics. The average NBV (adjusted for all the other baseline factors) was 14 cm 3 higher in FREEDOMS II than in FREEDOMS (p < 0.001) indicating significant trial effect. However, since the According to this criterion, 365 patients (15.5%) were categorized as having low NBV, 1610 (69%) as having medium NBV, and 367 (15.5%) as having high NBV (Figure 2(b) ). As the classification is individualized according to each patient's demographic and disease characteristics at baseline (Figure 1) , the same value of NBV can result in a different classification depending on the subject's characteristics. For example, an NBV of 1500 cm 3 would classify a young, non-disabled male patient with a low T2LV and a short disease duration in the low-NBV group, whereas the identical 1500 cm 3 NBV value in an elderly, highly disabled patient with a high T2LV and a long disease history, would fall into the high-NBV group (Figure 1) .
Prognostic value of the proposed NBV categories for predicting disability worsening
The impact of the categorization according to baseline NBV, adjusted for all the other relevant characteristics in the model, on the cumulative risk of 3-month CDP over 2 years is shown in Table 3 and Figure 3 . The probability of 2-year confirmed disability worsening, after adjusting for treatment effect, was associated with the NBV categorization (p = 0.002). Taking the high-NBV group as a reference, the hazard ratios (HRs) for the medium-NBV and low-NBV groups were 1.23 (95% confidence interval (CI): 0.92-1.63, p = 0.16) and 1.75 (95% CI: 1.26-2.44, p = 0.001), respectively. In placebo-treated patients, the proportion of patients with disability worsening was 20% (standard error (SE) 4%) in the high-NBV group, 25% (2%) (HR = 1.30, 95% CI: 0.83-2.05, p = 0.25) in the medium-NBV group, and 37% (5%) (HR = 2.13, 95% CI: 1.26-3.61, p = 0.005) in the low-NBV group.
The corresponding values in the fingolimod-treated patients were 16% (2%), 19% (1%), and 23% (3%), respectively (Figure 3(a) ).
The treatment effect tended to be more evident in patients in the low-NBV group (HR = 0.58, 95% CI: 0.38-0.88) than in patients in the medium-NBV (HR = 0.72, 95% CI: 0.57-0.90) and in the high-NBV (HR = 0.80, 95% CI: 0.47-1.36) groups. However, the treatment effect was not significantly different across the three NBV groups since the p value for interaction was not significant (p = 0.57).
A consistent pattern was also observed for cumulative risk of 6-month CDP over 2 years although fewer events occurred (data not shown). Furthermore, the prognostic value of NBV in predicting disability worsening was confirmed over longer periods, up to 4 years, using data from the FREEDOMS and FREEDOMS II extension studies (Figure 3(b) ).
Discussion
MS is a complex disease of the CNS. Although macroscopic, inflammatory lesions are the most evident aspect of MS pathology, a widespread pathology also occurs. 1 Global brain atrophy, which starts at the earliest stage of MS and progresses through disease course, is the expression of such diffuse tissue pathology. 10 While quantification is routinely used for High NBV: high observed normalized brain volume; low NBV: low observed normalized brain volume; medium NBV: medium observed normalized brain volume; NBV: normalized brain volume. MRI-derived assessment of lesions in clinical practice to guide clinical decisions 29 this is much less common for MRI-derived cross-sectional and longitudinal measures of atrophy. Including BVL as a cumulative measure of widespread pathology of the CNS in RRMS should provide a more comprehensive and balanced assessment of the patient disease course.
BV in MS depends on many demographic (age, sex) and clinical characteristics (disease duration, disability level, etc.). 17 In this study, we quantified the distribution of NBV in a large cohort of RRMS patients, adjusting for the relevant baseline characteristics in order to identify the NBV values of those subjects that are "far" from their expected values. Using this methodology, patients are classified as having a high, medium, or low NBV relative to all other patients with similar baseline characteristics. We demonstrated that it is possible to define values for each individual patient of what we called "eNBV" based on adjustments for disease-relevant covariates (T2LV, age, EDSS, disease duration, and sex) and proposed a formula which can be used to calculate the NBV cutoff for an individual patient. The putative clinical relevance of this was that, based on these individualized values of NBV, it is possible to identify patients who are at a higher risk for future disability worsening.
This analysis represents the first attempt to define individual cutoff values of BV, acknowledging the patients baseline characteristics. Our results suggest that the classification of patients into low, medium, High NBV: high observed normalized brain volume; low NBV: low observed normalized brain volume; medium NBV: medium observed normalized brain volume; NBV: normalized brain volume. and high NBV categories allows for a better characterization of the patient risk of future disability worsening and may inform individual management through the course of the disease. It needs to be stressed, however, that the approach used here has several limitations that restricts its utility in clinical practice. These include lack of standardization and varying quality in the MRI acquisition, as well as potential for inaccurate image post-processing. For example, data reported here might be different with different MRI acquisitions (e.g. field strength, voxel size, and type of sequence) or different imaging analysis (e.g. software packages different from SIENAX, and different imaging reading site). These can be relevant sources of error that can affect the measurement estimation. Additionally, generic factors, such as lifestyle habits, genetic load, and concomitant pathologic conditions may also affect BV measurements and need to be taken into account when interpreting brain atrophy, particularly in the single patient assessment. Despite the above limitations, progress in computational technologies allows to expect a more convincing clinical use of MRI-based brain volumetry in a number of neurological disorders, including RRMS. Further studies are needed an independent datasets to evaluate whether these cutoffs need to be re-calibrated after correcting for different MRI acquisition protocols and analysis pipelines.
In this study, the overall baseline average NBV was very similar between the two large, multicenter clinical datasets (FREEDOMS and FREEDOMS II) with distributions that were nearly superimposable. This is indicative of a great homogeneity in the NBV values, which is of paramount importance for the validity of the results. To create common cutoffs, there must be no systematic differences in NBV when measured in different settings. For this reason, these results need to be validated in other datasets to understand whether the same methodology and the same individualized values of NBV can be extended to other patient populations, especially to those beyond controlled clinical trials. Moreover, it is important to re-emphasize that this analysis was based on the NBV calculations using SIENAX and cannot be extended to other methods of BVL assessment. Finally, although SIENAX is a widely used, standard method in clinical trials, its use in clinical practice on individual patients might be challenging and requires experienced personnel to perform accurate measurements.
Patients included in clinical trials usually have active inflammatory activity, due to the inclusion criteria aimed at enriching patients for inflammatory activity at baseline. Whereas baseline inflammatory activity can affect the rate of BV change over time, the baseline value of NBV is much less affected by this and was not associated with MRI activity as assessed by gadolinium enhancement in this large dataset. From a more general perspective, NBV is a measure of the BV loss that occurred in the given patient, until the time of measurement. Thus, NBV is less intrinsically dependent on the inflammatory activity at the time, but rather depends on the overall disease burden. Therefore, the formula used to calculate the eNBV included the T2-lesion burden, as an expression of the overall focal pathology that may be associated to the baseline BV. As a consequence, the findings reported here may be generalizable to a typical clinic population of MS patients, composed of a mixture of active and inactive patients.
When discussing BV, brain reserve and cognitive reserve also need to be considered. Several studies have indicated that both, brain reserve and cognitive reserve, may serve as a buffer against future cognitive impairment. [30] [31] [32] Our findings generally support this concept, as we showed that individuals with a higherthan-eNBV had a better prognosis for disability worsening over 2 and 4 years, than those with a lower NBV. This suggests that a window of opportunity exists, wherein therapeutic interventions can be the most effective in delaying disease worsening implying that an early intervention with an effective disease-modifying therapy may be linked to a more favorable long-term outcome.
A number of studies have consistently shown a close correlation between BVL and disability worsening, particularly in the long term. 14, 17, 33 A recent post hoc analysis of data from the fingolimod phase III trials provided evidence that NBV at baseline was the strongest predictor of disability in RRMS patients and the correlation of BVL with worsening disability was stronger over 4 years than in the first 2 years on study. 17 The prognostic value of brain atrophy rates in predicting long-term disability has also been demonstrated in other studies. 14, 33 A large multicenter study reported that whole and central brain atrophy over 1 year can predict EDSS scores at 10 years in a heterogeneous group of MS patients. 14 In a follow-up study reassessing RRMS patients from a phase III trial of interferon β-1a, brain atrophy rate was found to be the best MRI predictor of disability status at the 8-year follow-up. 33 Consistent with these findings, we observed that the baseline NBV values in individual patients predicted disability worsening over 2-4 years.
In summary, we propose a methodology to calculate quantitative reference values for single-point NBV measurements that allow to identify patients having a lower value of BV than that expected according to their clinical and demographic profile. This classification can be used to assign RRMS patients to distinct risk groups regarding future disability worsening and may help physicians to identify and appropriately treat patients at a higher risk of disability worsening.
